Kazakhstan is taking a major step toward reducing its dependence on imported medicines. As part of the поручения of President Kassym-Jomart Tokayev, the country is carrying out systematic work to increase the share of domestic production in the pharmaceutical industry, DKNews.kz reports.
The Government has approved the conclusion of investment agreements between the Ministry of Health of Kazakhstan and four pharmaceutical companies. The total volume of investments under the approved projects amounts to 173 billion tenge. The corresponding resolutions were signed by Prime Minister Olzhas Bektenov.
Which companies are involved
The investment agreements were approved with the following companies:
- AltINFARM LLP
- MSP-ROMPHARM LLP
- Abdi Ibrahim Global Pharm LLP
- Nobel Almaty Pharmaceutical Factory JSC
The projects are aimed at localizing pharmaceutical production and launching the manufacture of critically important medicines within Kazakhstan.
What medicines will be produced in Kazakhstan
As a result of the projects, the production of 356 types of medicines will be localized, including a wide range of socially significant drugs.
The production portfolio will include medicines for the treatment of:
- oncological diseases
- diabetes mellitus
In addition, Kazakhstan will locally produce immunobiological, antiviral, anti-anemic, pain-relieving, anti-inflammatory, cold and flu, and antimicrobial medicines.
These categories represent some of the most sensitive and strategically important segments of the healthcare system.
Where new pharmaceutical plants will be built
New pharmaceutical enterprises will be located in:
- Almaty city - two projects
- Almaty region
- Turkestan region
This approach allows industrial development not only in the largest city, but also in the regions.
AltINFARM project - focus on biopharmaceuticals and oncology
AltINFARM LLP plans to build a pharmaceutical plant in the Park of Innovative Technologies Special Economic Zone in Almaty. The investment volume is estimated at 58.5 billion tenge.
The plant will produce 54 medicines, including 35 socially significant drugs. The production portfolio includes immunobiological medicines, as well as drugs for the treatment of cancer and diabetes. The project provides for the creation of around 60 new jobs.
Strategic partners include Sinopharm, Sinovac and Kangtai Biological Technology.
Nobel Almaty Pharmaceutical Factory - GMP-standard production
Another project in Almaty will be implemented by Nobel Almaty Pharmaceutical Factory JSC. The company plans to build a pharmaceutical complex for the production of active pharmaceutical ingredients, finished medicines and biopharmaceuticals in compliance with international GMP standards.
The investment volume will amount to 39.2 billion tenge. The production of 53 medicines is planned, including 17 socially significant drugs. At least 200 jobs will be created. The strategic partner is Nobel İlaç.
Abdi Ibrahim - a multi-profile pharmaceutical complex in Almaty region
Within the Abdi Ibrahim Global Pharm LLP project, a pharmaceutical complex with multi-profile production lines will be built in the Almaty region. The investment volume is 39 billion tenge.
The project предусматривает the production of 76 medicines, including antiviral drugs, medicines for the treatment of type II diabetes, and anti-anemic preparations. At least 150 jobs will be created. The strategic partner is Abdi Ibrahim.
TURAN SEZ - large-scale production of essential medicines
MSP-ROMPHARM LLP plans to build a high-tech pharmaceutical plant in the TURAN Special Economic Zone in the Turkestan region, as well as production sites in the Almaty region. The total investment volume is 36.7 billion tenge.
The plant will produce 101 medicines, including pain relievers, anti-inflammatory, cold and flu, and antimicrobial drugs. Around 265 jobs will be created. Project partners include World Medicine and Rompharm.
What this means for Kazakhstan
Overall, the implementation of the four investment projects will result in the creation of approximately 675 new jobs. The construction and commissioning of the plants will significantly increase the share of domestically produced medicines, reduce import dependence, and strengthen the stability of the pharmaceutical supply system.
The Government emphasizes that these projects will help ensure access to affordable and high-quality medicines made in Kazakhstan and will become an important element in strengthening national drug security and the long-term sustainability of the healthcare system.
